At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
Nasal Glucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Nasal Glucagon and Oxymetazoline for Common Cold. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant. The study will investigate how the body processes NG and the effect of NG on the body. The study will last up to 30 days for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesCanada
CollaboratorsLocemia Solutions ULC
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
Primary CompletionApr 2013
First PostedMay 2016
TodayJul 2026
First PostedMay 19, 2016
Enrollment StartMar 1, 2013
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 10.1 years ago
Interventions
Nasal Glucagondrug
Administered intranasally.
Oxymetazolinedrug
Administered intranasally.